Renovorx appoints james ahlers as chief financial officer

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of james ahlers as chief financial officer (cfo), effective july 15, 2022, and the addition of ronald b. kocak as vice president and controller for renovorx. mr. ahlers replaces christopher j. lehman, who joined renovorx in connection with its initial public offering and is leaving to pursue a new business opportunity. mr. a
RNXT Ratings Summary
RNXT Quant Ranking